# The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction

Study · id `cardio:ct-nct07103655` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07103655](<https://clinicaltrials.gov/study/NCT07103655>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07103655

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 132 participants.

## Technical summary

Registry record NCT07103655. Non-randomized; no masking; primary purpose treatment. Start 2026-03-01 (actual); primary completion 2026-11-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 132 participants (planned count; ClinicalTrials.gov record NCT07103655, source copy `cardio:ctgov-nct07103655-2026-09-15`, retrieved 2026-10-31)
- Started: 2026-03-01 (actual) (ClinicalTrials.gov record NCT07103655, source copy `cardio:ctgov-nct07103655-2026-09-15`, retrieved 2026-10-31)
- Primary completion: 2026-11-01 (anticipated) (ClinicalTrials.gov record NCT07103655, source copy `cardio:ctgov-nct07103655-2026-09-15`, retrieved 2026-10-31)
- Completion: 2027-01-01 (anticipated) (ClinicalTrials.gov record NCT07103655, source copy `cardio:ctgov-nct07103655-2026-09-15`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07103655, source copy `cardio:ctgov-nct07103655-2026-09-15`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07103655-2026-09-15`, retrieved 2026-10-31)

## The registry's words

- Brief title: The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction
- Acronym: BRAVE-HCM
- Condition: Hypertrophic Cardiomyopathy (HCM)
- Intervention (Drug): mavacamten
- Intervention (Drug): Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol
- Intervention (Drug): diltiazem
- Lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry intervention name matches this record: Mavacamten (`cardio:mavacamten`)
- Registry intervention name matches this record: Diltiazem (`cardio:diltiazem`)
- Registry lists this organization as the lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine (`cardio:org-second-affiliated-hospital-zhejiang-university-school-of-bfd3ac`)

## Provenance

Content hash: 5aad7a1548bfb25a1c646bbc468a5484136ace6483f1a3452ffed5fa45b3ae97
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
